Related Experiment Video
Updated: Aug 1, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Some statistical issues in HIV vaccine trials
1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Abstract:
Efficacy trials of prophylactic HIV vaccines will be among the most difficult clinical trials ever attempted. Not only will there be challenges with the recruitment and retention of high-risk uninfected individuals, there will be many statistical challenges to the design, conduct, analysis, and interpretation of these trials. General features of an efficacy trial are described, including choice for the primary endpoint and testing for and estimating vaccine efficacy. Secondary objectives of trials are also discussed. These include determining the correlates of protective immunity, assessing the impact of HIV genetic variation on vaccine efficacy, and using biological markers such as viral load and CD4+ lymphocyte cell count to gain insight on a vaccine's ability to prevent or delay disease. The use of biological markers as surrogates for disease outcome is discussed. Last, trial designs for studying several candidate vaccines or other HIV prevention strategies in a single trial are examined.
More Related Videos
Related Concept Videos
Statistical Significance
Clinical Trials
There are four phases in a clinical trial. A phase one...
Confounding in Epidemiological Studies
Bias in Epidemiological Studies
Statistical Methods for Analyzing Epidemiological Data

